03:26 Beijing time on September 21, 2021, OTC market in the United StatesWUHAN GENERAL GP (WUHN.us)The stock changed, and the stock price quickly fell by 7.92%. As of press time, the stock was trading at US $0.608 per share, with a turnover rate of 0.005% and an amplitude of 0.005%.
Recent earnings data show that the stock achieved operating income of $2362.00, net profit of-$281603.00, earnings per share of-$0.010, gross profit of $419.00, and a price-to-earnings ratio of-74.12 times.
In terms of agency rating, there is currently no agency to make "buy, hold, sell" recommendations on the stock.
In the pharmaceutical industry in which WUHAN GENERAL GP's shares are located in the US OTC market, the overall decline was 0.94 per cent. Among its related stocksPetros Pharmaceuticals Inc、AstraZeneca PLC、Amphastar Pharmaceuticals IncThe increase is relatively large.Clarus Therapeutics Hldgs Inc、Tilray Inc、Sundial Growers IncRelatively active, with turnover rates of 8.49%, 5.06% and 4.18%, respectively. The related stocks with larger amplitudes areClever Leaves Holdings Inc C/Wts 18 + 12 * 2025 (To Pur Com)、Flora Growth Corp.、REGENCELL BIOSCIENCE HLDGS LTDThe amplitudes are 18.80%, 16.86% and 15.53%, respectively.
About WUHAN GENERAL GP in American OTC Market: M2Bio Sciences Inc, formerly known as WUHAN GENERAL GP Group (China) Co., Ltd., is an alternative pharmaceutical company dedicated to the application of emerging technologies and clinical research and health applications of cannabinol (CBD)-based drugs in the human and pet care industries in Canada, the United States, Europe and Australia for cancer, cardiovascular disease, and mental illness. Chronic pain and other diseases. It provides medical-grade CBD products and quality patient care.
(the above content is completed by Money Call, a self-selected intelligent machine writer, and is only used as a reference for users to look at the market, not as a basis for transaction. )